Journal of Molecular Medicine & Therapeutics#

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Short Communication, Mol Med Ther Vol: 1 Issue: 1

Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease

Tessa M. Simone and Paul J. Higgins*
Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York 12208, USA
Corresponding author : Paul J. Higgins
Center for Cell Biology & Cancer Research, Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208, USA
Tel: 518-262-5168; Fax: 518-262-5669
E-mail: [email protected]
Received: July 16, 2012 Accepted: August 02, 2012 Published: August 05, 2012
Citation: Simone TM, Higgins PJ (2012) Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease. Mol Med Ther 1:1 doi:10.4172/2324-8769.1000102

Abstract

Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease

Plasminogen activator inhibitor-1 (PAI-1; SERPINE1) is the major physiologic regulator of the plasmin-based pericellular proteolytic cascade, a modulator of vascular smooth muscle cell (VSMC) migration and a causative factor in cardiovascular disease and restenosis, particularly in the context of increased vessel transforming growth factor- β1 (TGF-β1) levels. PAI-1 limits conversion of plasminogen to plasmin (and, thereby, fibrin degradation) by inhibiting its protease targets urokinase and tissuetype plasminogen activators (uPA, tPA).

Keywords:

Track Your Manuscript

Share This Page